Annette Frost

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 333 citations

Medicine, Oncology, Pharmacology +17

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

Medicine, Oncology, Pharmacology +16

Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps.

R. G. Sarre, Annette Frost, David G. Jagelman et al. · Gut · 1987 · 204 citations · Full text

Medicine, Oncology, Pathology +15

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling et al. · Clinical Cancer Research · 2009 · 169 citations

Medicine, Oncology, Pharmacology +16

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Journal of Clinical Oncology · 2008 · 158 citations · Full text

Pharmacy, Oncology, Pharmacology +14